Publisher
Springer Berlin Heidelberg
Reference30 articles.
1. Aapro M, Crawford J, Kamioner D (2010) Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 18:529–541
2. Averbuch D, Orasch C, Cordonnier C et al (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98:1826–1835
3. Bundesärztekammer WBD (2014) Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten, 4., überarb. u. aktual. Aufl. 2014. In: Bundesärztekammer (Hrsg) Bundesärztekammer, S 1–392
4. Crawford J, Kreisman H, Garewal H et al (1997) The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 8:1117–1124
5. Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93